

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.


Please cancel claims 1-9, 14, 19, and 30 without prejudice to their presentation in another application, and amend claims 26-30 as follows:

1-20. (canceled).

21. (previously presented) A compound which is
(±)-7-methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one,
(±)-2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl}
amino)benzoic acid,
(±)-2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-
yl]ethyl}amino)benzonitrile,
(±) methyl 2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-
yl]ethyl}amino)benzoate, or
(±)-7-methyl-2-(morpholin-4-yl)-9-(1- {2-(2*H*-tetrazol-5-yl)phenyl}amino)ethyl)-
pyrido[1,2-a]pyrimidin-4-one.

22-25. (canceled).

26. (currently amended) A compound according to formula (I):



(I)

wherein[[,]] :

R is H, C₁-C₆ branched or straight chain alkyl, [[or]] aryl₁ or (CH₂)_n-aryl;

R₁ is H, OH, OCH₃, OCF₃, F, Cl, CF₃, C₁-C₆ branched or straight chain alkyl, [[or]] aryl₁ or (CH₂)_n-aryl;

R₂ is C₁-C₆ branched or straight chain alkyl, [[or]] aryl₁ or (CH₂)_n-aryl in either the R or the S configuration;

R₃ is one or more of H, F, Cl, Br, I, CN, CO₂H, CO₂R, NO₂, CF₃, substituted or unsubstituted C₁-C₆ alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH₃, OCH₂F, OCHF₂, OCF₃, OR, OSO₂-aryl, substituted or unsubstituted amine, NHCOR, NHSO₂R, CONHR, or SO₂NHR;


X is C or N₂ and

Y is N or O.

27. (currently amended) A method for ~~inhibiting phosphoinositide 3-kinase, preventing or treating cardiovascular disease, preventing or treating respiratory disease, preventing or treating cancer, or preventing or treating disease linked to disordered white blood cell function,~~

comprising administering an effective amount of ~~any one of the compounds~~ a compound of claim 26 to a patient in need thereof.

28. (currently amended) ~~The A method of claim 27, treating cardiovascular disease~~
comprising administering the 2-morpholino-substituted derivative of formula (I) wherein:



R is H, C₁-C₆ branched or straight chain alkyl, or aryl;

R₁ is H, OH, OCH₃, OCF₃, F, Cl, CF₃, or C₁-C₆ branched or straight chain alkyl;

R₂ is C₁-C₆ branched or straight chain alkyl, or aryl in either the R or the S configuration;

R₃ is one or more of H, F, Cl, Br, CN, CO₂H, CO₂R, NO₂, CF₃, branched or straight chain C₁-C₆ alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, OCH₃, OCH₂F, OCHF₂, OCF₃, OR, substituted or unsubstituted amine, NHCOR, NHSO₂R, CONHR, or SO₂NHR;

X is C or N; and

Y is N or O.

29. (currently amended) The method of claim 27, wherein the inhibitor administered is selected from the group consisting of:

(±)-7-methyl-9-{[methyl(phenyl)amino]methyl}-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-195);

(±)-7-methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one (TGX-221);

(±)-7-methyl-2-morpholin-4-yl-9-[1-(4-fluorophenylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-224);

(±)-9-[1-(3,4-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-237);

(±)-9-[1-(2,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-238);

(±)-9-[1-(3,5-difluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-239);

(±)-9-[1-(4-fluoro-2-methylphenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-240);

(±)-9-[1-(4-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-243);

(±)-9-[1-(3,4-dichlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-244);

(±)-9-[1-(3-fluorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-247);

(±)-9-[1-(3-chlorophenylamino)ethyl]-7-methyl-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-248);

(±)-7-methyl-2-morpholin-4-yl-9-[1-(2-thiazolylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-261);

(±)-7-methyl-9-[1-(3-methylphenylamino)ethyl]-2-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one (TGX-262);

(±)-7-methyl-2-morpholin-4-yl-9-[1-(3-trifluoromethylphenylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-264); [[and]]

(±)-7-methyl-2-morpholin-4-yl-9-[1-(2-pyridinylamino)ethyl]-pyrido[1,2-a]pyrimidin-4-one (TGX-295)[[.]] ;

(±)-2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl} amino)benzoic acid (KN-309);

(±) methyl 2-({ 1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl} amino)benzoate (KN-321);

~~(±) 2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl} amino)benzonitrile (KN-320);~~

(±)-2-({1-[7-methyl-2-(morpholin-4-yl)-4-oxo-pyrido[1,2-a]pyrimidin-9-yl]ethyl} amino)benzonitrile (KN-320);

(±)-7-methyl-2-(morpholin-4-yl)-9-(1-{[2-(2H-tetrazol-5-yl)phenyl] amino} ethyl)-pyrido[1,2-a]pyrimidin-4-one (KN-325); and

(±)-2-(4-morpholinyl)-8-[1-(phenylamino)ethyl]-4H-1-benzopyran-4-one (TGX-280).

30. (canceled).